Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Gladstone's Lennart Mucke and Keith Vossel are featured in an article about the growing body of research into the connection between Alzheimer’s disease and epilepsy—research that is providing hope for the 5 million patients currently suffering from the disease.
Gladstone's Warner C. Greene joins with other HIV/AIDS experts to discuss the possibility of curing HIV/AIDS, in a videotape of an October event in San Francisco.
Gladstone's Warner C. Greene comments on new research from Johns Hopkins University, which suggestst that the search-and-destroy mission against HIV just got much more complicated.
Do your genes inexorably write your destiny with respect to your fitness and health? The answers—in an article penned by Gladstone President R. Sanders "Sandy" Williams, MD, in the new online news site launched by Carlos Watson—may surprise you.
Once Gladstone negotiates the right to use a drug sitting on a biotech company's shelf, a clinical trial could be up and running within six to 12 months.
Nearly 100 people gathered at the State Building in San Francisco on Tuesday to hear the latest news on HIV cure research, a field that has seen remarkable, if slow, progress over the past few years. Sponsored by the UCSF AIDS Research Institute, the Gladstone Institutes, and the California Institute for Regenerative Medicine, the town hall featured Gladstone's Warner C. Greene and others.
Experts—including Gladstone's Warner C. Greene—discussed the latest news on HIV cure research at a well-attended town hall forum in San Francisco on October 1.
Researchers at the Gladstone Institutes and the University of California, San Francisco, are evaluating next-generation sequencing for its ability to detect early signs of drug resistance in HIV patients. In an Illumina-sponsored webinar, Gordon Bentley, a senior research associate at Gladstone, discussed his group's use of deep amplicon sequencing of the HIV reverse transcriptase gene to look for known mutations conferring resistance to antiretroviral drugs.
In the race for a cure for HIV, the wins are stacking up. Scientists are searching for a cure that's affordable and safe, and will shut down the epidemic entirely.
Researchers at San Francisco's Gladstone Institutes are being awarded more than $12 million in grants from divisions of the National Institutes of Health to help develop an elusive knock-out punch against AIDS.